← SynDRA
MARAVIROC
SynDRA canonical compound SYN0009157 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | CCR5 | CYP3A5 |
|---|
| Mechanism of action | CC chemokine receptor antagonist |
|---|
| Indication | human immunodeficiency virus (HIV-1) |
|---|
| Disease area | infectious disease |
|---|
All known targets
Mechanisms of action (all sources)
- CCR5 ANTAGONIST
- C-C chemokine receptor type 5 antagonist
- CC chemokine receptor antagonist
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- ACHE
- HDAC6
- HTR1A
- HTR2B
- KCND3
- KCNH2
- KDR
- MAOA
- OPRM1
- PDE3A
- PDE4A
- PGR
- PTGS1
- SLC6A2
- SLC6A3
- SLC6A4
- TBXA2R
- HRH3
- F2
- ADORA3
- ESR1
- ADRA1A
- ADRA2A
- AR
- CACNA1C
- CHRM1
- CHRM2
- CXCR4
- CXCR5
- CYP1A2
- CYP2C19
- CYP2C9
- CYP2D6
- CYP3A4
- DRD1
- DRD3
- YES1
Drug classes
- Chemokine Co-receptor 5 Antagonists
- CCR5 Co-receptor Antagonist
- Anti-HIV Agents
- Anti-Infective Agents
- Anti-Retroviral Agents
- Antiviral Agents
- CCR5 Receptor Antagonists
- HIV Fusion Inhibitors
ATC classes
- J05A · DIRECT ACTING ANTIVIRALS
Cross-references
Synonyms
- SELZENTRY
- Selzentry
- MD6P741W8A
- UK-427857
- maravirok
- marawirok
- celsentri
- selzentry
- Rel-maraviroc
- Uk-427,857
- Celsentri
- UK 427857
- UK-427,857
- UNII-MD6P741W8A
- CHEMBL256907
- MVC
- CHEMBL1201187
- CHEBI:63608
- Maraviroc [USAN]
- Celsentri (TN)
- Celsentri(TM)
- PRO 140 & Maraviroc
- Selzentry (TN)
- Selzentry(TM)
- UK-427,857 maraviroc (MVC)
- [3H]maraviroc
Reported adverse events
- Hepatotoxicity
- Rash
- Myositis
- Stevens-Johnson syndrome
- Infection
- Acne
- Alopecia
- Anxiety
- Bronchitis
- Conjunctivitis
- Constipation
- Cough
Look up MARAVIROC in the interactive SynDRA portal →